Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

CEMACH Release: New Results On The Perinatal Mortality Rate
The latest figures from the Confidential Enquiry into Maternal and Child Health (CEMACH) Perinatal Mortality Surveillance Report 2007 show improvements in the stillbirth and neonatal death rates in the UK.
generic viagra online
Senate Confirms Hamburg As FDA Commissioner
The Senate on Monday by voice vote confirmed Margaret Hamburg as FDA commissioner, CQ HealthBeat reports (CQ HealthBeat, 5/18). As commissioner, Hamburg is expected to immediately begin working on the agency"s response to the H1N1 flu virus. She also has said she wants to overhaul the agency"s food safety efforts. According to CongressDaily, Hamburg hopes to restore confidence in the agency, which has experienced controversy surrounding drug and food safety issues in recent years (CongressDaily, 5/19). Hamburg is the 21st FDA commissioner and the second woman to hold the position in FDA"s 100-year history (AP/Washington Post, 5/19).
News of the day
Mathematical Model Shows Why Defeating Insurgent Groups Like Taliban Is So Difficult
Insurgent groups like the Taliban can only be effectively engaged with timely and accurate military intelligence, and even good intelligence may only succeed in containing the insurgency, not defeating it, according to a new study in the current issue of Operations Research, a flagship journal of the Institute for Operations Research and the Management Sciences (INFORMS®).
Nutrition

Hebrew University Research Leads To Advanced Trials Of New Cancer Treatment

Research by a Hebrew University of Jerusalem professor has led to the development of a product that has been shown in clinical trials to be successful in halting the growth of various types of cancer cells. The research, conducted by Prof. Avraham Hochberg of the Silberman Institute of Life Sciences at the university, has won for him first prize among faculty members for this year"s Kaye Innovations Awards, which was presented on June 9 during the annual Hebrew University Board of Governors meeting. Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells. Research has also demonstrated that the H19 gene plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions, such as low serum and low oxygen levels, that are typical conditions of the environment in which cancerous cells develop. This survival supports the growth of the tumor and the development of metastases. The research and understanding of the origin of cancer and metastases has progressed significantly in recent years. In light of scientific breakthroughs in cancer research, and the role of the H19 gene in such processes, it is believed that an anti-cancer drug based on suppressing the expression of the H19 gene has the potential to provide benefits that are competitive with existing treatment methods. Prof. Hochberg"s research was patented by Yissum Research Development Company of the Hebrew University. In 2005 Yissum established BioCancell Inc., to which it licensed the technology. The company is now traded in the Tel Aviv stock exchange (TASE). BioCancell"s leading product, BC-819, has demonstrated efficacy in clinical trials (now in an advanced stage) in Israel and the US for the treatment of human bladder, pancreatic and ovarian cancers. Jerry Barach The Hebrew University of Jerusalem


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009